Extended Data Fig. 4: Characterization of SLAMF6+TSL across tissues.
From: Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
a, Flow cytometry plot showing correlation of PD-1 and SLAMF6 protein expression on OVA-tetramer+ CD8+ T cells from Day 10 tdLN. b, Mean SLAMF6 fluorescence intensity on different subsets of OVA-tetramer+ cells across different tissues. SLAMF6 expression was particularly enriched in TCF-1+ TSL residing in tdLN, as shown by the normalized SLAMF6 expression (normalized to naïve TCF-1+PD-1-CD8+ T cells) in (c). d, Bcl-2 expression (normalized to naïve TCF-1+PD-1-CD8+ T cells) and e, mean fluorescence intensity of CD200 expressed on each subset of OVA-tetramer+ CD8+ T cells. Data from 2 independent experiments (n = 6) for (b-c), 3 independent experiments (n = 11) for (d), and 2 independent experiments (n = 7) for (e). f-g, Relative expression of H2AK119Ub by different subsets of OVA-tetramer+ cells from different tissues, shown in representative histograms (f) and as mean fluorescence intensities (normalized to naïve TCF-1+PD-1-CD8+ T cells) (g). h-k, Quantification of CX3CR1 and CD39 expressions on OVA-tetramer+ subsets in the tdLN. Histogram panels showing the relative expression across subsets (h, j) and the proportions of positive gated events (i, k) based on thresholds shown as dashed lines in the histogram panels. Data from 2 independent experiments (n = 6). Error bars: means ± s.d. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired two-tailed t-test (b, c) and one-way ANOVA with Tukey’s multiple comparisons for all others.
